Thomson Reuters Corp vs Health Care Select Sector SPDR Fund — how do they compare? Thomson Reuters Corp trades at $100.95 (market cap $43.21B), while Health Care Select Sector SPDR Fund trades at $168.16 (market cap $43.11B). The key difference: Thomson Reuters Corp and Health Care Select Sector SPDR Fund are close in size by market cap, and Thomson Reuters Corp pays a 2.64% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Thomson Reuters Corp for 63 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| TRI | XLV | |
|---|---|---|
Market Cap | $43.21B | $43.11B |
Volume | 1,017,653 | 8,870,090 |
Sector | Industrials | — |
52-Week High | $163.45 | $175.68 |
52-Week Low | $76.55 | $141.95 |
Typical Hold Time | 63 Days | 100 Days |
Enterprise Value | $45.82B | — |
Dividend Yield | 2.64% | — |
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) stock trades at $101.55, up 3.53% today, showing strong momentum amid positive technical signals and fundamental strength. The company demonstrates robust profitability with 75.7% gross margins and 21.22% net income margins, supported by 10% organic growth in core businesses. Recent developments include the successful divestment of its printing unit and the launch of proprietary AI technology, positioning TRI for continued growth in the legal and professional information markets.
With analyst consensus pointing to 31% upside to the $133.25 price target and strong institutional buying, TRI presents a compelling growth opportunity. However, investors should monitor execution risks around AI integration and potential cybersecurity vulnerabilities following recent incidents. The stock's current valuation at 26.16x P/E appears reasonable given the company's recurring revenue model and market leadership position.
XLV trades at $168.81, up 1.03% with a bullish technical signal from moving averages. The healthcare ETF shows strength with 61 diversified holdings and a low 0.08% expense ratio. Recent news highlights its defensive characteristics during market volatility and potential benefits from rising interest rates. Technical indicators show support at $168 with resistance at $170, while oscillators remain neutral.
XLV offers defensive exposure to healthcare with cost efficiency, though concentration in S&P 500 stocks limits global diversification. Political uncertainty and sector-specific risks like FDA approvals present challenges, but the ETF's broad diversification and historical performance during rate hikes support a constructive outlook for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →